High Density Lipoprotein: A Therapeutic Target in Type 2 Diabetes.
10.3803/EnM.2013.28.3.169
- Author:
Philip J BARTER
1
Author Information
1. Centre for Vascular Research, The University of New South Wales Faculty of Medicine, Sydney, Australia. pbarter@ozemail.com.au
- Publication Type:Review
- Keywords:
Lipoproteins, HDL;
Diabetes;
Atherosclerosis
- MeSH:
Atherosclerosis;
Cholesterol, HDL;
Glucose;
Humans;
Insulin;
Insulin-Secreting Cells;
Life Style;
Lipoproteins, HDL;
Motor Activity;
Muscle, Skeletal;
Smoke;
Smoking;
Weight Loss
- From:Endocrinology and Metabolism
2013;28(3):169-177
- CountryRepublic of Korea
- Language:English
-
Abstract:
High density lipoproteins (HDLs) have a number of properties that have the potential to inhibit the development of atherosclerosis and thus reduce the risk of having a cardiovascular event. These protective effects of HDLs may be reduced in patients with type 2 diabetes, a condition in which the concentration of HDL cholesterol is frequently low. In addition to their potential cardioprotective properties, HDLs also increase the uptake of glucose by skeletal muscle and stimulate the synthesis and secretion of insulin from pancreatic beta cells and may thus have a beneficial effect on glycemic control. This raises the possibility that a low HDL concentration in type 2 diabetes may contribute to a worsening of diabetic control. Thus, there is a double case for targeting HDLs in patients with type 2 diabetes: to reduce cardiovascular risk and also to improve glycemic control. Approaches to raising HDL levels include lifestyle factors such as weight reduction, increased physical activity and stopping smoking. There is an ongoing search for HDL-raising drugs as agents to use in patients with type 2 diabetes in whom the HDL level remains low despite lifestyle interventions.
